View ValuationVoyageur Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Voyageur Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 26Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 7.5 million in fundingVoyageur Pharmaceuticals Ltd. announced a non-brokered private placement for aggregate gross proceeds of a minimum of CAD 4,000,000 and a maximum of CAD 7,500,000 on March 24, 2026. The offering will include up to 57,692,307 units (assuming no flow-through shares are issued) at a price of CAD 0.13 per unit for gross proceeds of CAD 7,499,999.91, or/and up to 14,705,882 flow-through common shares at a price of CAD 0.17 per share for gross proceeds of CAD 2,499,999.94. Each unit shall consist of one common share and one common share purchase warrant. Each warrant shall entitle the holder to purchase one common share at a price of CAD 0.20 for a period of 36 months following the closing date of the offering. The company may pay a cash commission or finder's fee to qualified non-related parties of up to 8% of the aggregate gross proceeds of the offering payable in cash, together with warrants representing up to 8% of the units issued in connection with the offering. Each broker warrant will entitle the holder to purchase one additional common share at a price of CAD 0.13 for a period of 36 months following closing of the offering. The offering is expected to close on or about April 23, 2026, or such other date as the company may determine, and in any event, on or before a date not later than 45 days after the date of the news release announcing the offering. After an initial closing for not less than the minimum offering proceeds, the offering may close in multiple tranches. the offering is subject to certain conditions, including but not limited to, the receipt of all necessary approvals including the approval of the TSXV.お知らせ • Apr 08Voyageur Pharmaceuticals Ltd., Annual General Meeting, Jun 18, 2025Voyageur Pharmaceuticals Ltd., Annual General Meeting, Jun 18, 2025.お知らせ • Dec 19Voyageur Pharmaceuticals Ltd. announced that it has received CAD 0.913881 million in fundingOn December 18, 2024. Voyageur Pharmaceuticals Ltd. has closed the final tranche of the transaction.お知らせ • Oct 18Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 1 million in fundingVoyageur Pharmaceuticals Ltd. announced a non-brokered private placement that it will issue up to 16,666,667 units at an issue price of CAD 0.06 per unit for the gross proceeds of up to CAD 1,000,000 on October 17, 2024. Each Unit shall be comprised of one common share in the capital of the Corporation and one Common Share purchase warrant, each Warrant exercisable into one Common Share at a price of CAD 0.10 per share for thirty-six months from the date of issuance. The Warrants will include an acceleration provision whereby if the Common Shares trade at a price greater than CAD 0.25 for a period of 10 trading days, Voyageur may accelerate the expiry of the Warrants. Voyageur may pay a cash commission or finder's fee to qualified non-related parties of up to 8% of the gross proceeds of the Offering and issue broker warrants equal to up to 8% of the number of Units sold in the Offering. The Offering is being offered to all of the existing shareholders of Voyageur who are permitted to subscribe pursuant to the Existing Shareholder Exemption. This offer is open until November 27, 2024, or such other date or dates as the Corporation determines and one or more closings are expected to occur, with the first closing anticipated for on or about November 5, 2024. Completion of the Offering is subject to regulatory approval including, but not limited to, the approval of the TSX Venture Exchange. The Common Shares, Warrants and Broker Warrants issued will be subject to a four month and one day hold period from the date of issuance. Insiders of the Corporation may participate in the Offering.お知らせ • Sep 20Voyageur Pharmaceuticals Ltd. Appoints Iryna Saranchova as Chief Science OfficerVoyageur Pharmaceuticals Ltd. announced the appointment of Dr. Iryna Saranchova M.D., Ph.D., as its new Chief Science Officer (CSO), pending regulatory approval. Dr. Saranchova, a distinguished expert in clinical research and immunology, brings a wealth of experience that will further accelerate the Companys scientific endeavors. With a remarkable career as Chief Clinical Officer at MYND Life Sciences, Dr. Saranchova has led ground-breaking research in NeuroInflammation, OsteoImmunology, and OncoImmunology. Her leadership in developing and implementing clinical studies has set new standards within the industry, showcasing her ability to foster successful collaborations on a global scale. Dr. Saranchova has served as an Honorary Professor/Lecturer at the Faculty of Medicine, University of British Colombia (UBC), and as a Research Fellow at prestigious institutions, such as the Michael Smith Laboratories and the Vancouver Prostate Center. Her experience spans biomarker discovery, clinical research, and the development of immunotherapies. Dr. Saranchovas extensive publication portfolio in leading scientific journals, including Frontiers in Immunology, Frontiers in Pharmacology, and Scientific Reports, highlights her pioneering work in cancer immunotherapy and immune escape mechanisms in metastatic tumors. Her intellectual property portfolio, which includes several cancer related patents, reflects her commitment to advancing healthcare through innovative research and development. Her leadership will be integral to guiding the Companys development of a fullerene-based platform for multi-functional applications and ensuring compliance with FDA requirements for its current suite of barium and iodinated contrast medium drugs.お知らせ • Mar 01Voyageur Pharmaceuticals Ltd. announced that it has received CAD 0.4885 million in fundingOn March 1, 2024, Voyageur Pharmaceuticals Ltd. closed the transaction. The company announced that it has issued 6,106,250 Units at an issue price of CAD 0.08 per unit for the gross proceeds of CAD 488,500. Each unit shall be comprised of one common share and one common share purchase warrant, each warrant exercisable at cad 0.15 for twenty-four months from closing. In connection with the Offering, Voyageur paid cash commissions to qualified non-related parties of CAD 10,440 and issued an aggregate of 130,500 broker warrants. Each Broker Warrant entitles the holder to acquire one Common Share at a price of CAD 0.08 per Broker Warrant for a period of one (1) year from the date of issuance.お知らせ • Jan 17Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 0.8 million in fundingVoyageur Pharmaceuticals Ltd. announced a proposed non brokered private placement of up to 10,000,000 units at a price of CAD 0.08 per unit for gross proceeds of up to CAD 800,000 on January 16, 2024. Each unit shall be comprised of one common share and one common share purchase warrant, each warrant exercisable at cad 0.15 for twenty-four months from closing. The company may pay a cash commission or finder's fee of up to CAD 64,000 and issue broker warrants of up to 800,000 broker warrants. Each broker warrant will entitle the holder to acquire one common share at a price of CAD 0.08 per broker warrant for a period of one year from the date of issuance. The company will close the transaction in one or more tranches, with the final closing anticipated for on or about February 8, 2024. The completion of the offering is subject to regulatory approval including, but not limited to, the approval of the TSX Venture Exchange. The common shares and warrants issued will be subject to a four month hold period from the date of the closing of the offering. insiders of the company may participate in the offering.お知らせ • Aug 03Voyageur Pharmaceuticals Ltd. Announces Board ChangesVoyageur Pharmaceuticals Ltd. announced the retirement from the board of directors of the corporation (the board) of Ron Sifton who has served the company well for the last three and a half years as a member of the board and as chairman of the audit committee, and member of the compensation committee and corporate governance committee. Mr. Sifton received special thanks from the Board members and management and best wishes in his retirement. The company announced that Kevin R. McBeth, CPA, CA, ICD.D, subject to regulatory approval, has joined the Board and will take on the role of Chair of the Audit Committee as well as member of the Compensation Committee. Kevin is an accomplished and esteemed professional with a diverse background in finance, accounting, and corporate governance. With an extensive track record in the industry, Kevin has earned a reputation as a trusted advisor and distinguished leader. As a Certified Public Accountant (CPA) and Chartered Accountant (CA), Kevin possesses an in-depth understanding of financial management, reporting, and compliance. His proficiency lies in effectively managing complex financial operations, ensuring utmost accuracy and transparency in financial statements, and implementing robust internal controls. Kevin's unwavering commitment to excellence and his dedication to professional growth drove him to achieve the prestigious ICD.D (Institute of Corporate Directors) designation. This credential showcases his comprehensive knowledge of corporate governance practices, enabling him to provide strategic guidance to boards of directors. With this certification, Kevin is excellently equipped to contribute to the effective governance and long-term prosperity of Voyageur. Throughout his career, Kevin has held various executive positions, showcasing his leadership skills and business acumen. Serving as Chief Financial Officer (CFO) for prominent companies, he expertly oversees financial planning and analysis, budgeting, risk management, and successful mergers and acquisitions. His sharp financial insights, combined with a strategic mindset, have driven remarkable growth, and optimized financial performance for the organizations he has collaborated with.お知らせ • Jun 13Voyageur Pharmaceuticals Ltd. Announces the Release of the White PaperVoyageur Pharmaceuticals Ltd. announced the release of the white paper titled "SmoothX: A Promising New Positive Oral contrast Agent for CT."Authored by Alec J. Megibow, MD, MPH, FACR, the white paper highlights the remarkable imaging properties of Voyageur's product, SmoothX, emphasising its potential to optimize abdominal CT examinations and maximize patient satisfaction. Oral contrast agents have long been vital in elevating diagnostic accuracy and effectiveness in medical imaging procedures. With the introduction of SmoothX, Voyageur is offering a positive oral contrast agent that not only enhances diagnostic outcomes but also provides a pleasant taste, enhancing patient satisfaction. In a recent blinded study comparing SmoothX with the established oral contrast agent Readi- CAT2, Voyageur conducted a detailed evaluation, demonstrating that SmoothX exhibited nearly identical diagnostic imaging properties. This finding establishes SmoothX as a reliable alternative that maintains the uncompromising standards of image quality required for precise diagnosis. Of notable importance is the taste test study conducted alongside the clinical evaluation. The results revealed a remarkable preference for the palatable flavor of SmoothX among the majority of the participants compared to Readi-CAT2. This preference for SmoothX's taste has the potential to translate into heightened patient satisfaction and increased compliance during abdominal CT examinations. Voyageur extends heartfelt appreciation to the dedicated team at Canada Diagnostic Centre in Calgary for their invaluable participation in this study. Under the exceptional leadership of Jay Zelazo, MD, FRCPC, Director of CT, along with Jordan Muth, MRT (MR), MRI & CT Manager, and Michelle Holstein, Radiological Technologist, MRT (R) (MR), the study was meticulously executed, contributing significantly to the credibility and reliability of the findings. SmoothX represents a leap forward in oral contrast agents for CT imaging, aiming to provide a superior patient experience while ensuring optimal diagnostic outcomes. Voyageur remains steadfast in its commitment to continuous innovation, dedicated to improving the quality of care for patients worldwide.お知らせ • Jan 21Voyageur Pharmaceuticals Ltd. announced that it has received CAD 1.199949 million in fundingOn January 20, 2023, Voyageur Pharmaceuticals Ltd. closed the transaction. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Voyageur Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:VYYR.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数2/28/20260-3-2-2N/A11/30/20250-4-3-3N/A8/31/20250-3-2-2N/A5/31/2025N/A-2-1-1N/A2/28/2025N/A-2-1-1N/A11/30/2024N/A-200N/A8/31/2024N/A-200N/A5/31/2024N/A-1-10N/A2/29/2024N/A-1-1-1N/A11/30/2023N/A-1-1-1N/A8/31/2023N/A-2-1-1N/A5/31/2023N/A-2-2-2N/A2/28/2023N/A-2-2-2N/A11/30/2022N/A-2-2-2N/A8/31/2022N/A-2-2-2N/A5/31/2022N/A-2-2-1N/A2/28/2022N/A-2-2-2N/A11/30/2021N/A-2-2-2N/A8/31/2021N/A-2-1-1N/A5/31/2021N/A-1-1-1N/A2/28/2021N/A-1-10N/A11/30/2020N/A-100N/A8/31/2020N/A-1-1-1N/A5/31/2020N/A-1-1-1N/A2/29/2020N/A-1-1-1N/A11/30/2019N/A-1N/A-1N/A8/31/2019N/A-1N/A0N/A5/31/2019N/A-1N/A0N/A2/28/2019N/A-1N/A0N/A11/30/2018N/A-1N/A0N/A8/31/2018N/A0N/A-1N/A5/31/2018N/A-1N/A-1N/A2/28/2018N/A-1N/A-1N/A11/30/2017N/A-1N/A-1N/A8/31/2017N/A-1N/A0N/A5/31/2017N/A-1N/A0N/A2/28/2017N/A-1N/A0N/A11/30/2016N/A-1N/A0N/A8/31/2016N/A-1N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VYYR.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: VYYR.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: VYYR.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: VYYR.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: VYYR.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VYYR.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 05:12終値2026/06/03 00:00収益2026/02/28年間収益2025/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Voyageur Pharmaceuticals Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Daniel AppiahCapital Network by Proactive Investors
お知らせ • Mar 26Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 7.5 million in fundingVoyageur Pharmaceuticals Ltd. announced a non-brokered private placement for aggregate gross proceeds of a minimum of CAD 4,000,000 and a maximum of CAD 7,500,000 on March 24, 2026. The offering will include up to 57,692,307 units (assuming no flow-through shares are issued) at a price of CAD 0.13 per unit for gross proceeds of CAD 7,499,999.91, or/and up to 14,705,882 flow-through common shares at a price of CAD 0.17 per share for gross proceeds of CAD 2,499,999.94. Each unit shall consist of one common share and one common share purchase warrant. Each warrant shall entitle the holder to purchase one common share at a price of CAD 0.20 for a period of 36 months following the closing date of the offering. The company may pay a cash commission or finder's fee to qualified non-related parties of up to 8% of the aggregate gross proceeds of the offering payable in cash, together with warrants representing up to 8% of the units issued in connection with the offering. Each broker warrant will entitle the holder to purchase one additional common share at a price of CAD 0.13 for a period of 36 months following closing of the offering. The offering is expected to close on or about April 23, 2026, or such other date as the company may determine, and in any event, on or before a date not later than 45 days after the date of the news release announcing the offering. After an initial closing for not less than the minimum offering proceeds, the offering may close in multiple tranches. the offering is subject to certain conditions, including but not limited to, the receipt of all necessary approvals including the approval of the TSXV.
お知らせ • Apr 08Voyageur Pharmaceuticals Ltd., Annual General Meeting, Jun 18, 2025Voyageur Pharmaceuticals Ltd., Annual General Meeting, Jun 18, 2025.
お知らせ • Dec 19Voyageur Pharmaceuticals Ltd. announced that it has received CAD 0.913881 million in fundingOn December 18, 2024. Voyageur Pharmaceuticals Ltd. has closed the final tranche of the transaction.
お知らせ • Oct 18Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 1 million in fundingVoyageur Pharmaceuticals Ltd. announced a non-brokered private placement that it will issue up to 16,666,667 units at an issue price of CAD 0.06 per unit for the gross proceeds of up to CAD 1,000,000 on October 17, 2024. Each Unit shall be comprised of one common share in the capital of the Corporation and one Common Share purchase warrant, each Warrant exercisable into one Common Share at a price of CAD 0.10 per share for thirty-six months from the date of issuance. The Warrants will include an acceleration provision whereby if the Common Shares trade at a price greater than CAD 0.25 for a period of 10 trading days, Voyageur may accelerate the expiry of the Warrants. Voyageur may pay a cash commission or finder's fee to qualified non-related parties of up to 8% of the gross proceeds of the Offering and issue broker warrants equal to up to 8% of the number of Units sold in the Offering. The Offering is being offered to all of the existing shareholders of Voyageur who are permitted to subscribe pursuant to the Existing Shareholder Exemption. This offer is open until November 27, 2024, or such other date or dates as the Corporation determines and one or more closings are expected to occur, with the first closing anticipated for on or about November 5, 2024. Completion of the Offering is subject to regulatory approval including, but not limited to, the approval of the TSX Venture Exchange. The Common Shares, Warrants and Broker Warrants issued will be subject to a four month and one day hold period from the date of issuance. Insiders of the Corporation may participate in the Offering.
お知らせ • Sep 20Voyageur Pharmaceuticals Ltd. Appoints Iryna Saranchova as Chief Science OfficerVoyageur Pharmaceuticals Ltd. announced the appointment of Dr. Iryna Saranchova M.D., Ph.D., as its new Chief Science Officer (CSO), pending regulatory approval. Dr. Saranchova, a distinguished expert in clinical research and immunology, brings a wealth of experience that will further accelerate the Companys scientific endeavors. With a remarkable career as Chief Clinical Officer at MYND Life Sciences, Dr. Saranchova has led ground-breaking research in NeuroInflammation, OsteoImmunology, and OncoImmunology. Her leadership in developing and implementing clinical studies has set new standards within the industry, showcasing her ability to foster successful collaborations on a global scale. Dr. Saranchova has served as an Honorary Professor/Lecturer at the Faculty of Medicine, University of British Colombia (UBC), and as a Research Fellow at prestigious institutions, such as the Michael Smith Laboratories and the Vancouver Prostate Center. Her experience spans biomarker discovery, clinical research, and the development of immunotherapies. Dr. Saranchovas extensive publication portfolio in leading scientific journals, including Frontiers in Immunology, Frontiers in Pharmacology, and Scientific Reports, highlights her pioneering work in cancer immunotherapy and immune escape mechanisms in metastatic tumors. Her intellectual property portfolio, which includes several cancer related patents, reflects her commitment to advancing healthcare through innovative research and development. Her leadership will be integral to guiding the Companys development of a fullerene-based platform for multi-functional applications and ensuring compliance with FDA requirements for its current suite of barium and iodinated contrast medium drugs.
お知らせ • Mar 01Voyageur Pharmaceuticals Ltd. announced that it has received CAD 0.4885 million in fundingOn March 1, 2024, Voyageur Pharmaceuticals Ltd. closed the transaction. The company announced that it has issued 6,106,250 Units at an issue price of CAD 0.08 per unit for the gross proceeds of CAD 488,500. Each unit shall be comprised of one common share and one common share purchase warrant, each warrant exercisable at cad 0.15 for twenty-four months from closing. In connection with the Offering, Voyageur paid cash commissions to qualified non-related parties of CAD 10,440 and issued an aggregate of 130,500 broker warrants. Each Broker Warrant entitles the holder to acquire one Common Share at a price of CAD 0.08 per Broker Warrant for a period of one (1) year from the date of issuance.
お知らせ • Jan 17Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 0.8 million in fundingVoyageur Pharmaceuticals Ltd. announced a proposed non brokered private placement of up to 10,000,000 units at a price of CAD 0.08 per unit for gross proceeds of up to CAD 800,000 on January 16, 2024. Each unit shall be comprised of one common share and one common share purchase warrant, each warrant exercisable at cad 0.15 for twenty-four months from closing. The company may pay a cash commission or finder's fee of up to CAD 64,000 and issue broker warrants of up to 800,000 broker warrants. Each broker warrant will entitle the holder to acquire one common share at a price of CAD 0.08 per broker warrant for a period of one year from the date of issuance. The company will close the transaction in one or more tranches, with the final closing anticipated for on or about February 8, 2024. The completion of the offering is subject to regulatory approval including, but not limited to, the approval of the TSX Venture Exchange. The common shares and warrants issued will be subject to a four month hold period from the date of the closing of the offering. insiders of the company may participate in the offering.
お知らせ • Aug 03Voyageur Pharmaceuticals Ltd. Announces Board ChangesVoyageur Pharmaceuticals Ltd. announced the retirement from the board of directors of the corporation (the board) of Ron Sifton who has served the company well for the last three and a half years as a member of the board and as chairman of the audit committee, and member of the compensation committee and corporate governance committee. Mr. Sifton received special thanks from the Board members and management and best wishes in his retirement. The company announced that Kevin R. McBeth, CPA, CA, ICD.D, subject to regulatory approval, has joined the Board and will take on the role of Chair of the Audit Committee as well as member of the Compensation Committee. Kevin is an accomplished and esteemed professional with a diverse background in finance, accounting, and corporate governance. With an extensive track record in the industry, Kevin has earned a reputation as a trusted advisor and distinguished leader. As a Certified Public Accountant (CPA) and Chartered Accountant (CA), Kevin possesses an in-depth understanding of financial management, reporting, and compliance. His proficiency lies in effectively managing complex financial operations, ensuring utmost accuracy and transparency in financial statements, and implementing robust internal controls. Kevin's unwavering commitment to excellence and his dedication to professional growth drove him to achieve the prestigious ICD.D (Institute of Corporate Directors) designation. This credential showcases his comprehensive knowledge of corporate governance practices, enabling him to provide strategic guidance to boards of directors. With this certification, Kevin is excellently equipped to contribute to the effective governance and long-term prosperity of Voyageur. Throughout his career, Kevin has held various executive positions, showcasing his leadership skills and business acumen. Serving as Chief Financial Officer (CFO) for prominent companies, he expertly oversees financial planning and analysis, budgeting, risk management, and successful mergers and acquisitions. His sharp financial insights, combined with a strategic mindset, have driven remarkable growth, and optimized financial performance for the organizations he has collaborated with.
お知らせ • Jun 13Voyageur Pharmaceuticals Ltd. Announces the Release of the White PaperVoyageur Pharmaceuticals Ltd. announced the release of the white paper titled "SmoothX: A Promising New Positive Oral contrast Agent for CT."Authored by Alec J. Megibow, MD, MPH, FACR, the white paper highlights the remarkable imaging properties of Voyageur's product, SmoothX, emphasising its potential to optimize abdominal CT examinations and maximize patient satisfaction. Oral contrast agents have long been vital in elevating diagnostic accuracy and effectiveness in medical imaging procedures. With the introduction of SmoothX, Voyageur is offering a positive oral contrast agent that not only enhances diagnostic outcomes but also provides a pleasant taste, enhancing patient satisfaction. In a recent blinded study comparing SmoothX with the established oral contrast agent Readi- CAT2, Voyageur conducted a detailed evaluation, demonstrating that SmoothX exhibited nearly identical diagnostic imaging properties. This finding establishes SmoothX as a reliable alternative that maintains the uncompromising standards of image quality required for precise diagnosis. Of notable importance is the taste test study conducted alongside the clinical evaluation. The results revealed a remarkable preference for the palatable flavor of SmoothX among the majority of the participants compared to Readi-CAT2. This preference for SmoothX's taste has the potential to translate into heightened patient satisfaction and increased compliance during abdominal CT examinations. Voyageur extends heartfelt appreciation to the dedicated team at Canada Diagnostic Centre in Calgary for their invaluable participation in this study. Under the exceptional leadership of Jay Zelazo, MD, FRCPC, Director of CT, along with Jordan Muth, MRT (MR), MRI & CT Manager, and Michelle Holstein, Radiological Technologist, MRT (R) (MR), the study was meticulously executed, contributing significantly to the credibility and reliability of the findings. SmoothX represents a leap forward in oral contrast agents for CT imaging, aiming to provide a superior patient experience while ensuring optimal diagnostic outcomes. Voyageur remains steadfast in its commitment to continuous innovation, dedicated to improving the quality of care for patients worldwide.
お知らせ • Jan 21Voyageur Pharmaceuticals Ltd. announced that it has received CAD 1.199949 million in fundingOn January 20, 2023, Voyageur Pharmaceuticals Ltd. closed the transaction.